Tests nerve procedures for resistant high blood pressure and type 2 diabetes
Tests nerve-calming catheter procedures in adults with resistant hypertension and diabetes.
Plain-language title generated from the registry record
Registry title: The RESPLASH Study
Key facts
- Where
- New Orleans, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06880562, who can take part
Where in United States
- East Jefferson General HospitalNew Orleans, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tulane University
- Trial code
- NCT06880562
- Record updated
- 30 September 2026
- Original description
To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.Read full original descriptionShow less
Renal and Splanchnic Sympathetic Denervation as an Alternative Therapy for Resistant Hypertension and Type 2 Diabetes (RESPLASH Study)
To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.
Inclusion: Patients aged 18-75; History of Type 2 Diabetes Mellitus at least 5 years prior to enrollment; HbA1c level ≥6.5%; Use of at least 1 oral antidiabetic agent and no changes in the last 30 days; History of essential hypertension with systolic Blood pressure of 160 mmHg or more (≥150 mmHg in patient with Type 2 Diabetes Mellitus), despite compliance with three of more antihypertensive drugs; Stable drug regimen of at least 3 antihypertensive medications with no changes for 2 weeks before enrollment.
Exclusion: History of myocardial infarction, unstable angina, or cerebrovascular accident in the previous 3 months; History of previous renal artery CDN; Type 1 diabetes mellitus; History of aortic pathologies such as aneurysm or dissection confirmed by immediate preprocedural angiography that would preclude the Endovascular Denervation (EDN) procedure; Acute or severe systemic infection; Estimated glomerular filtration rate of less than 30 mL/min per 1.73m2; Orthostatic hypotension; Pregnancy or planned pregnancy during the study period; Unable to provide informed consent.